Company

Location

Amount (US$M)

Round

Details

Date

Total: $1,360.26M

4D Molecular Therapeutics Inc.

Emeryville, Calif.

$90.00

Series B

$90M series B financing led by Viking Global Investors

9/6/18

4D Molecular Therapeutics Inc.

Emeryville, Calif.

$0.50

N/A

$500,000 investment from the CureDuchenne venture philanthropy nonprofit to advance the firm's gene therapy

9/10/18

Akrevia Therapeutics Inc.

Cambridge, Mass.

$30.00

Series A

$30M series A round led by F-Prime Capital Partners and Atlas Venture

9/28/18

Allogene Therapeutics

South San Francisco

$120.00

N/A

$120M private financing of convertible notes

9/7/18

A-Mansia Biotech SA

Amsterdam, the Netherlands

$21.10

Series A

€18M (US$21.1M) in a series A round with investors including Innovation Industries

9/28/18

Aruna Biomedical Inc.

Athens, Ga.

$5.30

N/A

$5.3M from existing angel investors

9/28/18

Atreca Inc.

Redwood City, Calif.

$125.00

Series C

$125M series C round led by an existing investor – an unnamed U.S.-based health care-focused fund – with participation from existing investors Wellington Management Co. LLC and Cormorant Asset Management and new investors Aisling Capital, Boxer Capital of the Tavistock Group, Ecor1 Capital, Redmile Group, Samsara Biocapital and funds managed by Tekla Capital Management; Cowen served as exclusive placement agent

9/12/18

Auctus Biologics Inc.

Lafayette, N.Y.

$1.50

Seed

$1.5M in seed funding

9/24/18

Azeria Therapeutics Ltd.

Cambridge, UK

$5.13

Series A

£4M (US$5.13M) in series A fundraising from the £70M (US$89.8M) CRT Pioneer Fund, managed by Sixth Element Capital LLP, a U.K.-based fund manager

9/5/18

Bioaegis Therapeutics Inc.

Morristown, N.J.

$4.10

N/A

Closed a $4.1M equity round and has begun patient enrollment in a. The company is focused on an approach to address infectious, inflammatory and degenerative diseases through a portfolio built around rhu-pGSN technology.

9/19/18

Cadrock Pty Ltd.

Sydney

$5.00

Seed

$5M seed investment from a Chinese investor

9/5/18

Coda Biotherapeutics Inc.

South San Francisco

$19.00

Series A

$19M series A financing that drew lead investors MPM Capital and Versant Ventures with participation from Astellas Venture Management and Novartis

9/13/18

ENB Therapeutics Inc.

New York

N/A

Series A

Undisclosed series A round; Remiges Ventures served as lead investor with participation from New York State Development, Bioadvance and Alexandria Ventures

9/21/18

Evox Therapeutics Ltd.

Oxford, UK

$46.10

Series B

£35.5M (US$46.1M) series B round led by Redmile Group, with GV, Cowen Healthcare Investments, Pancea Healthcare Venture, Borealis Ventures and a small number of business angels investing for the first time; existing investors Oxford Sciences Innovation and Oxford University followed on

9/4/18

Exocobio Inc.

Seoul, South Korea

$27.00

Series B

$27M from a series B funding round

9/13/18

Feldan Therapeutics Inc.

Quebec City

$12.50

Series A

$12.5M in a series A financing led by parent company GC Holdings Corp., the recently rebranded Korean conglomerate that also houses GC Pharma, formerly Green Cross Corp; participants in the round included South Korea's Stonebridge Ventures and Anges Québec Capital and members – a previous seed investor – along with undisclosed existing investors

9/19/18

Forendo Pharma Oy

Turku, Finland

$4.65

N/A

€4M (US$4.65M) from Vesalius Biocapital III Partners

9/6/18

Fulcrum Therapeutics Inc.

Cambridge, Mass.

$80.00

Series B

$80M series B round led by Foresite Capital, and including Fidelity Management and Research Co., 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments and entities affiliated with Leerink Partners, along with undisclosed institutional investors

9/6/18

Galera Therapeutics Inc.

Malvern, Pa.

$150.00

Series C

$150M from a joint, oversubscribed series C financing and royalty purchase agreement; the financing includes a $70M equity raise and an $80M royalty financing payable from future sales of GC-4419 for severe oral mucositis in patients with head and neck cancer; lead investor Clarus Ventures will receive single-digit future commercial royalties from the sales of GC-4419 and a related pipeline asset until the total royalty amount achieves an undisclosed multiple of the initial $80M upon which the royalty terminates; the financing was led by new investor Clarus, with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital and Tekla Capital Management LLC; existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures also participated

9/20/18

Harbour Biomed Therapeutics Ltd.

Shanghai

$85.00

Series B

$85M series B round from GIC Private Ltd, and other investors including China Life Private Equity Investment Co. and Vertex Ventures, as well as series A investors Advantech and Legend Capital Management Co. Ltd.

9/4/18

Horama SAS

Paris

$4.30

Series B

Belgian fund V-Bio Ventures has joined its series B financing round initiated in October last year with a $4.3M investing, bringing the total raised to €22.5M (US$26.3M)

9/19/18

Ilya Pharma AB (Uppsala, Sweden)

Uppsala, Sweden

$3.48

N/A

€3M (US$3.48 million) in a new targeted share issue

9/11/18

Immune-Onc Therapeutics Inc.

Palo Alto, Calif.

$33.00

Series B

$33M from investors, including Northern Light Venture Capital, Vivo Capital and the Stanford-Startx Fund

9/20/18

Lyra Therapeutics Inc.

Watertown, Mass.

$29.50

Series B

$29.5M in a series B round led by Perceptive Advisors and includes new investors RA Capital Management, Arrowmark Partners and Soleus Capital, as well as participation by existing investors Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners

9/27/18

Minoryx Therapeutics SL

Barcelona, Spain

$25.00

Series B

€21.3M (US$25M) in a series B round

9/27/18

Morphic Therapeutics Inc.

Waltham, Mass.

$80.00

Series B

Existing investor Omega Funds linked up with new backer Novo Holdings to co-lead the $80 million series B co-led by Omega Funds and Novo Holdings; new investors Invus and Ecor1 Capital and Morphic's other series A investors joined the round

9/26/18

Oncoresponse Inc.

Seattle

$40.00

Series B

$40M series B round led by Rivervest Venture Partners, with participation from new investors, Redmile Group and Qatar Investment Authority; existing investors in Oncoresponse, Alexandria Venture Investments, Arch, the HT Family Office, Canaan, Helsinn Investment Fund and William Marsh Rice University, also participated

9/12/18

Orphan Star Therapeutics LLC

New York

$20.00

N/A

$20M from an undisclosed pharmaceutical partner

9/26/18

Phasebio Pharmaceuticals Inc.

Malvern, Pa.

$34.00

Series D

$34 million series D financing, including the conversion of existing convertible promissory notes

9/6/18

Phoenix Molecular Designs Ltd.

Vancouver, British Columbia

$2.70

N/A

$2.7M financing led by Pallasite Ventures; it also included angel investors, while $670,000 was nondilutive capital

9/19/18

Silverback Therapeutics Inc.

Seattle

$47.50

Series A

Extension of its series A round, previously cited only in SEC filings, to $47.5M; the financing was led by existing investor Orbimed with participation from new investors Celgene Corp. and Alexandria Venture Investments

9/20/18

System1 Biosciences Inc.

San Francisco

$25.00

Series A

$25M series A financing co-led by CRV and Pfizer Ventures with participation from Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb Investment Network, Liquid 2 Ventures and Boom Capital

9/13/18

Tierra Biosciences (formerly Synvitrobio Inc.)

San Francisco

$2.60

Seed

$2.6M seed round, led by Social Capital, with participation from Fifty Years and Kdt Ventures

9/12/18

Tolremo Therapeutics AG

Zurich

$9.30

Series A

Oversubscribed series A financing round of CHF9M (US$9.3M); the Swiss venture capital firm Biomedpartners AG led the round and was joined by Swiss venture capital firms Redalpine and Altos Venture, as well as Tolremo's existing shareholders, including the Swiss bank Zurcher Kantonalbank and several biotech investors

9/26/18

Tvardi Therapeutics Inc.

Houston

$9.00

Series A

$9M series A financing round

9/24/18

Twentyeight-Seven Therapeutics Inc.

Cambridge, Mass.

$65.00

Series A

$65M series A from seed investor MPM Capital, which co-led with Novartis Venture Fund, and included JJDC Inc., Vertex Ventures HC, Longwood Fund, and Astellas Venture Management

9/7/18

Ubiome

San Francisco

$83.00

Series C

$83M series C financing round

9/24/18

Viacyte Inc.

San Diego

$10.00

N/A

$10M in the form of a convertible promissory note

9/26/18

Virion Therapeutics LLC

Philadelphia

$5.00

N/A

$5M in a private financing

9/27/18


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

 

No Comments